CPT 81417: Exome Reanalysis for New Clinical Information
Commercial payers pay $332 on average nationally for this procedure.
CPT code 81417 describes a laboratory reanalysis of an existing patient exome sequencing result when new clinical information or previously unavailable evidence emerges; this service is a targeted reinterpretation of prior exome data to reassess variant classification and clinical significance. The service type is exome reanalysis / reinterpretation and the typical site of service is clinical molecular diagnostics laboratory performing genomic data review and reporting.
Customize your policy alerts
Sign up for cpt 81417 policy alerts
Get alerted when payer policies referencing 81417 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial reimbursement for CPT 81417 clusters around BUCA’s average commercial rate of $331.70, with individual payer medians and means showing meaningful variation. Blue Cross Blue Shield (BCBS) and Cigna exhibit higher central tendencies (BCBS median $324.40, Cigna median $286.70) while Aetna and UnitedHealth Group trend lower in median and mean levels; this places BUCA’s average near the upper middle of the payer mix.
Dispersion measured by the interquartile spread (P75 minus P25) highlights differences in consistency: Blue Cross Blue Shield has the widest IQR at $107.30 (P75 $381.90 minus P25 $274.60), followed by Cigna at $253.40 (P75 $417.90 minus P25 $164.50) and BUCA at $140.60 (P75 $361.10 minus P25 $220.50). Aetna is the tightest at $116.40 (P75 $262.40 minus P25 $146.00), with UnitedHealth Group showing moderate spread of $176.00 (P75 $320.00 minus P25 $134.40).